title: Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.
abstract: An expanding panel of monoclonal antibodies (mAbs) that specifically target malignant cells or intercept trophic factors delivered by the tumor stroma is now available for cancer therapy. These mAbs can exert direct antiproliferative/cytotoxic effects as they inhibit pro-survival signal transduction cascades or activate lethal receptors at the plasma membrane of cancer cells, they can opsonize neoplastic cells to initiate a tumor-targeting immune response, or they can be harnessed to specifically deliver toxins or radionuclides to transformed cells. As an indication of the success of this immunotherapeutic paradigm, international regulatory agencies approve new tumor-targeting mAbs for use in cancer patients every year. Moreover, the list of indications for previously licensed molecules is frequently expanded to other neoplastic disorders as the results of large, randomized clinical trials become available. Here, we discuss recent advances in the preclinical and clinical development of tumor-targeting mAbs for oncological indications.
authors.affiliation: Gustave Roussy Cancer Campus ; Villejuif, France ; INSERM; U1138 ; Paris, France ; Equipe 11 labellisée par la Ligue Nationale contre le Cancer; Centre de Recherche des Cordeliers ; Paris, France.
authors.forename: Erika
authors.initials: E
authors.lastname: Vacchelli
authors.affiliation: Gustave Roussy Cancer Campus ; Villejuif, France ; INSERM; U1138 ; Paris, France ; Equipe 11 labellisée par la Ligue Nationale contre le Cancer; Centre de Recherche des Cordeliers ; Paris, France.
authors.forename: Jonathan
authors.initials: J
authors.lastname: Pol
authors.affiliation: Gustave Roussy Cancer Campus ; Villejuif, France ; INSERM; U1138 ; Paris, France ; Equipe 11 labellisée par la Ligue Nationale contre le Cancer; Centre de Recherche des Cordeliers ; Paris, France.
authors.forename: Norma
authors.initials: N
authors.lastname: Bloy
authors.affiliation: Gustave Roussy Cancer Campus ; Villejuif, France.
authors.forename: Alexander
authors.initials: A
authors.lastname: Eggermont
authors.affiliation: INSERM; U1138 ; Paris, France ; Equipe 13; Centre de Recherche des Cordeliers ; Paris, France ; Université Pierre et Marie Curie/Paris VI ; Paris, France.
authors.forename: Isabelle
authors.initials: I
authors.lastname: Cremer
authors.affiliation: INSERM; U1138 ; Paris, France ; Equipe 13; Centre de Recherche des Cordeliers ; Paris, France ; Université Pierre et Marie Curie/Paris VI ; Paris, France.
authors.forename: Wolf Hervé
authors.initials: WH
authors.lastname: Fridman
authors.affiliation: INSERM; U1138 ; Paris, France ; Université Pierre et Marie Curie/Paris VI ; Paris, France ; Laboratory of Integrative Cancer Immunology; Centre de Recherche des Cordeliers ; Paris, France ; Université Paris Descartes/Paris V; Sorbonne Paris Cité ; Paris, France.
authors.forename: Jérôme
authors.initials: J
authors.lastname: Galon
authors.affiliation: Gustave Roussy Cancer Campus ; Villejuif, France ; INSERM ; U1015 , Villejuif, France.
authors.forename: Aurélien
authors.initials: A
authors.lastname: Marabelle
authors.affiliation: Department of Medicine; Division of Oncology; Stanford University ; Stanford, CA, USA.
authors.forename: Holbrook
authors.initials: H
authors.lastname: Kohrt
authors.affiliation: Gustave Roussy Cancer Campus ; Villejuif, France ; INSERM ; U1015 , Villejuif, France.
authors.forename: Laurence
authors.initials: L
authors.lastname: Zitvogel
authors.affiliation: INSERM; U1138 ; Paris, France ; Equipe 11 labellisée par la Ligue Nationale contre le Cancer; Centre de Recherche des Cordeliers ; Paris, France ; Université Paris Descartes/Paris V; Sorbonne Paris Cité ; Paris, France ; Pôle de Biologie; Hôpital Européen Georges Pompidou ; AP-HP ; Paris, France ; Metabolomics and Cell Biology Platforms; Gustave Roussy Cancer Campus ; Villejuif, France.
authors.forename: Guido
authors.initials: G
authors.lastname: Kroemer
authors.affiliation: Gustave Roussy Cancer Campus ; Villejuif, France ; INSERM; U1138 ; Paris, France ; Equipe 11 labellisée par la Ligue Nationale contre le Cancer; Centre de Recherche des Cordeliers ; Paris, France ; Université Paris Descartes/Paris V; Sorbonne Paris Cité ; Paris, France.
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Galluzzi
keywords: 5-fluorouracil; ADCC; Food and Drug Administration; FOLFIRI; acute lymphocytic leukemia; AML; acute myeloid leukemia; BiTE; anaplastic large-cell lymphoma; ALL; antibody-dependent cell-mediated cytotoxicity; ALCL; bevacizumab; bispecific T-cell engager; CDC; cetuximab; chronic lymphocytic leukemia; CRC; coagulation factor III; FDA; colorectal carcinoma; DLBCL; complement-dependent cytotoxicity; CLL; diffuse large B-cell lymphoma; EGFR; epidermal growth factor receptor; F3; folinic acid; hepatocellular carcinoma; HHV-8; human herpesvirus-8; IL; interleukin; mAb; irinotecan; FOLFOX; mantle cell lymphoma; MDS; monoclonal antibody; MMAE; monomethyl auristatin E; MCL; myelodysplastic syndrome; NHL; non-Hodgkin's lymphoma; NSCLC; non-small cell lung carcinoma; ORR; obinutuzumab; overall response rate; OS; overall survival; PFS; oxaliplatin; HCC; phosphoinositide-3-kinase; RCC; progression-free survival; PI3K; ramucirumab; renal cell carcinoma; SLL; rituximab; small lymphocytic leukemia; TAA; trastuzumab; tumor-associated antigen